Fund moves
3.7%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RNA · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Atrium Therapeutics (RNA) · oqro.io/stocks/RNA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$6.43−1.08 (−14.38%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
−90.9% (−$64.25) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $70.68 on Nov 17, 2025 to $6.43 on Nov 16, 2026 (−90.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Diego, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
−90.9%
Market value
$139M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.75M shares sold short (17.4% of shares outstanding), +0.6% vs the previous count, 16.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$15.3M
+24.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$25.8M
This quarter −$25.8M, a year earlier $833K
Net debt
—
Debt —, cash $44.6M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
No open-market purchase by an insider of Atrium Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Atrium Therapeutics (RNA) was filed with the SEC in the last 90 days.
No trade in Atrium Therapeutics (RNA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
4 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in cardiac glycogenosis. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Atrium Therapeutics over the 12 months to Nov 17, 2026: 1 clinical trial.